{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-020566","form_type":"8-K","ticker":"ESLA","cik":"0001844417","company_name":"Estrella Immunopharma, Inc.","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.943769+00:00","generated_at":"2026-06-05T01:54:30.069348+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Estrella Immunopharma signs $33M clinical trial SOW with Eureka for EB103 Phase I/II NHL trial","bullets":["Total fees of $33M for 20-patient Phase I/II trial of EB103 anti-CD19 ARTEMIS T-cell therapy in R/R B-cell NHL.","Initial invoice of $3.5M due upon execution; $1.5M deposit before dosing; $1.375M per patient for 20 patients.","Estimated dosing: 6 patients by end of 2024, 14 more by end of 2025; study close-out by end of 2025.","Eureka Therapeutics, controlling shareholder of Estrella, provides services; includes cooperation for financing compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-020566","json":"https://secwatch.observer/filing/0001213900-24-020566.json","markdown":"https://secwatch.observer/filing/0001213900-24-020566.md","text":"https://secwatch.observer/filing/0001213900-24-020566.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1844417/000121390024020566/0001213900-24-020566-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1844417/000121390024020566/ea0201282-8k_estrella.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:54:30.069348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}